Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2020, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.
Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 2, 5, 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2020, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.
Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 2, 5, 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Neuromyelitis Optica - Overview
Neuromyelitis Optica - Therapeutics Development
Neuromyelitis Optica - Therapeutics Assessment
Neuromyelitis Optica - Companies Involved in Therapeutics Development
Neuromyelitis Optica - Drug Profiles
Neuromyelitis Optica - Dormant Projects
Neuromyelitis Optica - Discontinued Products
Neuromyelitis Optica - Product Development Milestones
Appendix
Neuromyelitis Optica - Overview
Neuromyelitis Optica - Therapeutics Development
Neuromyelitis Optica - Therapeutics Assessment
Neuromyelitis Optica - Companies Involved in Therapeutics Development
Neuromyelitis Optica - Drug Profiles
Neuromyelitis Optica - Dormant Projects
Neuromyelitis Optica - Discontinued Products
Neuromyelitis Optica - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accendatech Au Pty Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accure Therapeutics SL, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ahead Therapeutics SL, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Aprilbio Co Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apsara Therapeutics, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, H2 2020
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accendatech Au Pty Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accure Therapeutics SL, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ahead Therapeutics SL, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Aprilbio Co Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apsara Therapeutics, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2020
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Accendatech Au Pty Ltd
Accure Therapeutics SL
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Aprilbio Co Ltd
Apsara Therapeutics
Bio-Thera Solutions Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Endece LLC
EnhanX Biopharm Inc
H. Lundbeck AS
HanAll Biopharma Co Ltd
ImCyse SA
Imstem Biotechnology Inc
LFB SA
Mitsubishi Tanabe Pharma Corp
Nanjing Iaso Biotherapeutics Co Ltd
NovelMed Therapeutics Inc
Orion BioScience Inc
RemeGen Ltd
Tolerion Inc
Viela Bio Inc
Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Accendatech Au Pty Ltd
Accure Therapeutics SL
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Aprilbio Co Ltd
Apsara Therapeutics
Bio-Thera Solutions Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Endece LLC
EnhanX Biopharm Inc
H. Lundbeck AS
HanAll Biopharma Co Ltd
ImCyse SA
Imstem Biotechnology Inc
LFB SA
Mitsubishi Tanabe Pharma Corp
Nanjing Iaso Biotherapeutics Co Ltd
NovelMed Therapeutics Inc
Orion BioScience Inc
RemeGen Ltd
Tolerion Inc
Viela Bio Inc
